市場調查報告書
商品編碼
1518360
血糖監測設備市場:依產品類型、糖尿病類型、最終用戶劃分 - 到 2030 年的全球預測Blood Glucose Monitoring Devices Market by Product (Self-monitoring {Glucometer, Test Strips, Lancets}, Continuous Glucose Monitoring {Sensors, Receiver, Transmitter}), Diabetes Type, End User (Self/Home Care, Hospital, Clinic) - Global Forecast to 2030 |
血糖監測設備市場預計到2030年將達到217.1億美元,2023年至2030年的複合年增長率為7.5%。
經過全面的一手和二手研究以及對市場情景的詳細分析,該報告包括對主要市場驅動因素、限制因素、機會和課題的分析。這個市場的驅動因素包括糖尿病盛行率上升、越來越多的人過著不健康和久坐的生活方式,以及糖尿病治療的產品創新。然而,保險範圍和報銷的不確定性以及產品召回正在限制市場成長。
此外,新興國家對非侵入性血糖監測設備的需求不斷增長,人們對糖尿病健康的認識不斷提高,預計將為該市場的參與者提供巨大的成長機會。然而,大量未確診的糖尿病患者和連續血糖監測設備的高成本是影響市場成長的主要課題。
依產品劃分,自我血糖監測設備預計將在 2023 年佔據血糖監測設備市場的最大佔有率。該細分市場的巨大市場佔有率歸因於 2 型糖尿病的高盛行率、對血糖監測設備中使用的試紙的持續需求以及人們對糖尿病自我管理的認識不斷增強等因素。
依糖尿病類型劃分,預計 2023 年 2 型糖尿病將佔據血糖監測設備市場的最大佔有率。該細分市場的巨大市場佔有率歸因於越來越多的人過著不健康的生活方式,缺乏體力活動,導致 2 型糖尿病的盛行率不斷上升。
從最終用戶來看,預計到 2023 年,自我照護/居家照護領域將佔據血糖監測設備市場的最大佔有率。由於使用血糖監測設備進行糖尿病自我管理的患者人數較多,且具有便利性和成本效益等優點,因此該細分市場擁有很大的市場佔有率。
到 2023 年,北美預計將佔據血糖監測設備市場的最大佔有率,其次是歐洲和亞太地區。北美市場規模之大得益於糖尿病管理意識高、連續血糖監測等新技術採用率高以及該地區人口購買力高。
Blood Glucose Monitoring Devices Market Size, Share, Forecast, & Trends Analysis by Product (Self-monitoring {Glucometer, Test Strips, Lancets}, Continuous Glucose Monitoring {Sensors, Transmitter}), Diabetes Type, End User- Global Forecast to 2030
The blood glucose monitoring devices market is projected to reach $21.71 billion by 2030, at a CAGR of 7.5% from 2023 to 2030.
Following comprehensive primary and secondary research and an in-depth analysis of the market scenario, this report provides an analysis of the key market drivers, restraints, opportunities, and challenges. This market is driven by the rising prevalence of diabetes, the increasing number of people living unhealthy & sedentary lifestyles, and product innovations in diabetes care. However, insurance coverage and reimbursement uncertainties and product recalls restrain the growth of this market.
Furthermore, the growing demand for non-invasive glucose monitoring devices and increasing awareness regarding diabetic health in developing countries are expected to generate significant growth opportunities for the players in this market. However, the large number of people living with undiagnosed diabetes and the high costs of continuous glucose monitoring devices are major challenges impacting market growth.
Based on product, in 2023, the self-monitoring devices segment is expected to account for the largest share of the blood glucose monitoring devices market. The large market share of this segment is attributed to factors such as the high prevalence of Type-2 diabetes, the recurring demand for test strips used with blood glucose monitoring devices, and increased awareness about diabetes self-management.
Based on diabetes type, in 2023, the Type-2 diabetes segment is expected to account for the largest share of the blood glucose monitoring devices market. The large market share of this segment is attributed to the increased prevalence of Type-2 diabetes due to the increasing number of people living unhealthy lifestyles without physical activity.
Based on end user, in 2023, the self/home care segment is expected to account for the largest share of the blood glucose monitoring devices market. The large market share of this segment is attributed to the large patient population utilizing blood glucose monitoring devices for the self-management of diabetes due to their advantages, such as convenience and cost-effectiveness.
In 2023, North America is expected to account for the largest share of the blood glucose monitoring devices market, followed by Europe and Asia-Pacific. North America's large market is attributed to the high awareness regarding diabetes management, high adoption of newer technologies such as continuous glucose monitoring, and higher purchasing power of the population in the region.
The key players operating in the blood glucose monitoring devices market are Abbott Laboratories (U.S.), Ascensia Diabetes Care Holdings AG (a subsidiary of PHC Holdings Corporation) (Switzerland), Becton, Dickinson and Company (U.S.), DexCom, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), LifeScan IP Holdings, LLC (a subsidiary of Platinum Equity, LLC, U.S.) (Switzerland), Medtronic plc (Ireland), Ypsomed Holding AG (Switzerland), B. Braun Melsungen AG (Germany), Nipro Corporation (Japan), ARKRAY, Inc. (U.S.), Prodigy Diabetes Care, LLC (U.S.), ACON Laboratories, Inc. (U.S.), and Nova Biomedical Corporation (U.S.).
Blood Glucose Monitoring Devices Market Assessment-by Product
Note: Other devices & accessories include hemoglobin A1c testing kits and non-invasive blood glucose monitoring devices.
Blood Glucose Monitoring Devices Market Assessment-by Diabetes Type
Blood Glucose Monitoring Devices Market Assessment-by End User
Note: Other end users include physician offices, ambulatory care settings, and diagnostics labs.
Blood Glucose Monitoring Devices Market Assessment-by Geography